Regulatory Teva Receives FDA Approval of Denosumab Biosimilar and Filing Acceptances by FDA and EMA For Omalizumab Biosimilar Big Molecule WatchOn March 30, 2026, Teva Pharmaceutical Industries Ltd.RegulatoryRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Big Molecule Watch On March 30, 2026, Teva Pharmaceutical Industries Ltd. RegulatoryRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly launches GLP-1 pill, kicking off showdown with Novo NordiskNext: Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers Related Stories Regulatory FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients pharminent June 2, 2026 Regulatory FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy pharminent June 1, 2026 Regulatory Replimune gives cancer immunotherapy a third try after FDA leadership shakeup pharminent May 29, 2026
